Boston Scientific to buy Penumbra in $14.5 billion deal
Jan 15 (Reuters) - Boston Scientific said on Thursday it will buy Penumbra in a deal valued at about $14.5 billion to expand its vascular pipeline.
The deal values Penumbra at $374 per share, a premium of about 19.3% to its last close. Penumbra's shares rose over 10% in premarket trading, while Boston's shares fell 4%.
The transaction is expected to be completed in 2026.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shreya Biswas)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bank of Singapore's Neutral Call on Asia-Ex Japan: A Capital-Preserving Play Amid Iran War Risks
Top 8 Coins to Watch in 2026: APEMARS ($APRZ) Stage 11 Could Turn $1K Into $50K – Next Crypto to Hit $1
Bitcoin Price Rally Fades, Market Braces for Possible Downside
Forecast Trading Expands with Polymarket Weather Markets
Trending news
MoreCrypto prices
More
